|
WO1997021728A1
(en)
|
1995-12-12 |
1997-06-19 |
Karolinska Innovations Ab |
PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7060670B1
(en)
|
1999-05-05 |
2006-06-13 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
|
AU2001273361A1
(en)
*
|
2000-07-11 |
2002-01-21 |
Molecular Geriatrics Corporation |
Reagents and methods for identification of binding agents
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
PE20020574A1
(en)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
|
PE20050627A1
(en)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
|
|
US7674599B2
(en)
|
2003-11-08 |
2010-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of using antibodies to detect alpha-synuclein in fluid samples
|
|
PE20061329A1
(en)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
|
|
US7625560B2
(en)
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
KR101439828B1
(en)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
|
JP5475994B2
(en)
|
2005-11-30 |
2014-04-16 |
アッヴィ・インコーポレイテッド |
Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
|
|
US8012936B2
(en)
|
2006-03-29 |
2011-09-06 |
New York University |
Tau fragments for immunotherapy
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
SI2182983T1
(en)
|
2007-07-27 |
2014-09-30 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
|
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
SI2408807T1
(en)
*
|
2009-03-18 |
2021-11-30 |
Ac Immune Sa |
Method for therapeutic use
|
|
UA107571C2
(en)
*
|
2009-04-03 |
2015-01-26 |
|
PHARMACEUTICAL COMPOSITION
|
|
CA2765099A1
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Phosphorylated tau peptide for use in the treatment of tauopathy
|
|
US8609097B2
(en)
|
2009-06-10 |
2013-12-17 |
Hoffmann-La Roche Inc. |
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
|
|
KR20130127547A
(en)
*
|
2009-07-30 |
2013-11-22 |
화이자 백신스 엘엘씨 |
Antigenic tau peptides and uses thereof
|
|
ES2684475T3
(en)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteins that bind to beta amyloid
|
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
|
JP6371526B2
(en)
*
|
2010-10-07 |
2018-08-08 |
エーシー イミューン エス．エー． |
Phosphorylated site-specific antibody that recognizes tau
|
|
AU2013205313B2
(en)
*
|
2010-10-07 |
2016-05-19 |
Ac Immune S.A. |
Phosphospecific antibodies recognising tau
|
|
AU2011315181B2
(en)
*
|
2010-10-11 |
2016-07-28 |
Biogen International Neuroscience Gmbh |
Human anti-tau antibodies
|
|
BR112014008202B1
(en)
*
|
2011-10-07 |
2022-01-04 |
Ac Immune S.A. |
ANTIBODY, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION, USES OF AN ANTIBODY, IN VITRO METHOD, METHOD OF DETECTION OF THE FORMATION OF AN IMMUNE COMPLEX, POSTMORTEM DETECTION METHOD OF PHOSPHO-TAU MULTIMERS, TEST KITS, ISOLATED CELL LINE AND MULTIMER DETECTION METHOD OF PHOSPHO-TAU
|
|
MX356800B
(en)
|
2012-04-05 |
2018-06-13 |
Ac Immune Sa |
Humanized tau antibody.
|
|
SG10201913370PA
(en)
|
2012-07-03 |
2020-03-30 |
Univ Washington |
Antibodies to tau
|
|
WO2014016737A1
(en)
*
|
2012-07-24 |
2014-01-30 |
Pfizer Inc. |
Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
|
|
ES2775192T3
(en)
|
2012-08-16 |
2020-07-24 |
Ipierian Inc |
Tauopathy treatment procedures
|
|
HRP20201422T1
(en)
|
2012-12-21 |
2021-02-19 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
|
US8980270B2
(en)
|
2013-01-18 |
2015-03-17 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
HRP20200384T1
(en)
|
2013-12-20 |
2020-06-12 |
F. Hoffmann - La Roche Ag |
HUMANIZED ANTI-TAU (PS422) ANTIBODIES AND METHODS OF USE
|
|
EP3104870A4
(en)
|
2014-02-14 |
2017-09-13 |
Ipierian, Inc. |
Tau peptides, anti-tau antibodies, and methods of use thereof
|
|
AR100978A1
(en)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
|
|
TWI734975B
(en)
|
2014-06-27 |
2021-08-01 |
美商Ｃ２Ｎ醫療診斷有限責任公司 |
Humanized anti-tau antibodies
|
|
US10132818B2
(en)
|
2014-07-08 |
2018-11-20 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
|
CN113929779B
(en)
|
2015-06-24 |
2025-02-25 |
豪夫迈·罗氏有限公司 |
Humanized anti-Tau (pS422) antibodies and methods of use
|
|
WO2017027685A2
(en)
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
CA3079423A1
(en)
|
2017-10-25 |
2019-05-02 |
Janssen Pharmaceuticals, Inc. |
Compositions of phosphorylated tau peptides and uses thereof
|
|
RU2020135052A
(en)
*
|
2018-03-28 |
2022-04-29 |
Аксон Ньюросайенс Се |
METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE BASED ON ANTIBODIES
|
|
JOP20210211A1
(en)
|
2019-02-08 |
2023-01-30 |
Janssen Pharmaceuticals Inc |
Method of safe administration of phosphorylated tau peptide vaccine
|
|
BR112021021213A2
(en)
|
2019-04-24 |
2021-12-21 |
Ac Immune Sa |
Heterologous administration of tau vaccines
|
|
KR102905634B1
(en)
*
|
2019-05-31 |
2025-12-30 |
일라이 릴리 앤드 캄파니 |
Compounds and methods targeting human tau
|